RT Journal Article
SR Electronic
T1 Characterisation of peri-implantation endometrial Treg and identification of an altered phenotype in recurrent pregnancy loss
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.22.21255931
DO 10.1101/2021.04.22.21255931
A1 Ingrid Granne
A1 Mengni Shen
A1 Helena Rodriguez-Caro
A1 Gurmeher Chadha
A1 Elizabeth O’Donnell
A1 Jan J. Brosens
A1 Siobhan Quenby
A1 Tim Child
A1 Jennifer H. Southcombe
YR 2021
UL http://medrxiv.org/content/early/2021/04/23/2021.04.22.21255931.abstract
AB Recurrent Pregnancy Loss (RPL) affects 2-4% of couples, and with increasing numbers of pregnancy losses the risk of miscarrying a euploid pregnancy is increased, suggesting RPL is a pathology distinct from sporadic miscarriage that is due largely to lethal embryonic aneuploidy. There are a number of conditions associated with RPL including unspecified ‘immune’ pathologies, one of the strongest candidates for dysregulation remains T regulatory cells as depletion in the very early stages of pregnancy in mice leads to pregnancy loss.Human endometrial Treg and conventional CD4T cells were isolated during the peri-implantation period of the menstrual cycle in normal women. We identified an endometrial Treg transcriptomic signature and validated an enhanced regulatory phenotype compared to peripheral blood Treg. Parous women had an altered endometrial Treg transcriptome compared to nulliparity, indicating acquired immunity memory of pregnancy within the Treg population, by comparison endometrial conventional CD4T cells were not altered. We compared primary and secondary RPL to nulliparous or parous controls respectively. Both RPL subgroups displayed differentially expressed Treg gene transcriptomes compared to controls. We found increased cell surface S1PR1 and decreased TIGIT protein expression by Treg in primary RPL, confirming the presence of altered Treg in the peri-implantation RPL endometrium.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding was from the IVI Foundation FINOX.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Oxford Research Ethics Committee C (ref:08/H0606/94).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request